|
| |
Image Results
Loading...
Loading...
BIAL - Portela C. SA Pages on BioPortfolio:
BioPortfolio - Bial
S.MAMEDE DO CORONADO, Portugal and LONDON, April 28 /PRNewswire/ -- Bial-Portela & CA, S.A., (S. Mamede do Coronado, Portugal, President & CEO Dr Luis ...
http://www.bioportfolio.com/biocorporate/19332-Bial.html...
|
BioPortfolio - Bial - Profile
Department of Research and Development, BIAL (Portela & Ca SA), S. Mamede- Int J Clin Pharmacol. Ther. 2008 Mar;46(3):119-30. Press Releases on Bial: ...
http://www.bioportfolio.com/biocorporate/19332-Bial.pdf...
|
BioPortfolio - BIA - Profile
Bial-Portela & CA, S.A., (S. Mamede do. Coronado, Portugal, President & CEO Dr. Luis Portela), and Eisai Europe Limited. Beyond Seizure Control in ...
http://www.bioportfolio.com/biocorporate/1360-BIA.pdf...
|
Results from other life science and pharmaceutical sites:
Bial-Portela & Ca. S.A. - Company Profile - BioCentury
Bial-Portela's detailed financings; Comprehensive pipeline breakdown, including molecular targets & partnerships. 17 years of in-depth BioPharma industry ...
http://www.biocentury.com/companies/Bial_Portela_and_Ca_SA?u...
|
Bial and Eisai Inc. Announce Novel Once Daily Anti-Epileptic ...
28 Apr 2009 ... Bial-Portela & CA, S.A., (S. Mamede do Coronado, Portugal, President & CEO Dr Luis Portela), and Eisai Europe Limited (London; ...
http://www.biospace.com/news_story.aspx?NewsEntityId=136815...
|
Sepracor - About Sepracor: Corporate Agreements
BIAL-Portela & Ca, S.A. (BIAL) In December 2007, Sepracor and BIAL entered into an exclusive licensing agreement for the development and commercialization ...
http://www.sepracor.com/aboutSepracor/corporateAgreements.ht...
|
Eisai Company, Ltd. and Bial Announce Partnership Agreement for ...
19 Feb 2009 ... Eisai Europe Ltd (London; Chairman & CEO Yutaka Tsuchiya), the European subsidiary of Eisai Co., Ltd. , and Bial-Portela & CA, S.A., ...
http://www.biospace.com/news_story.aspx?NewsEntityId=126959...
|
Pharmacokinetic-pharmacodynamic interaction between nebicapone and ...
Department of Research and Development, BIAL (Portela & Ca., S.A.), S. Mamede do Coronado, Portugal. Background: Nebicapone is a reversible ...
http://www.ncbi.nlm.nih.gov/pubmed/19922897?dopt=Abstract...
|
Sepracor - About Sepracor
These agreements have provided us with an antiepileptic candidate, STEDESA TM ( eslicarbazepine acetate), licensed from BIAL-Portela & Ca, S.A., ...
http://www.sepracor.com/aboutSepracor/aboutSepracor.html...
|
Zebinix a Novel Once Daily Anti-Epileptic Launched Today in the UK ...
8 Nov 2009 ... agreement with Bial - Portela & C(a), S.A. (Headquarters: São. ... Founded in 1924, Bial is an international pharmaceutical group with ...
http://biz.yahoo.com/prnews/091108/4013756en_uspublic.html?....
|
Effect of renal impairment on the pharmacokinetics of ...
Department of Research and Development, BIAL (Portela & Ca SA), S. Mamede do Coronado, Portugal. OBJECTIVE: Antiepileptic drugs are often used in patients
...
http://www.ncbi.nlm.nih.gov/pubmed/18397682...
|
Sepracor - Therapeutic Areas: Central Nervous System
In addition, we expanded our commitment to delivering CNS therapies by in- licensing an antiepileptic product candidate from BIAL-Portela & Ca, S.A., ...
http://www.sepracor.com/therapeuticAreas/centralNervousSyste...
|
Pharmacokinetics of eslicarbazepine acetate in patients with ...
Department of Research and Development, BIAL (Portela & Ca SA), A Av. da Siderurgia Nacional, 4745-457, S Mamede do Coronado, Portugal. ...
http://www.ncbi.nlm.nih.gov/pubmed/18157705...
|
|
